Personalis (NASDAQ:PSNL) Price Target Raised to $12.00 at Needham & Company LLC

Personalis (NASDAQ:PSNL) had its target price increased by analysts at Needham & Company LLC from $10.00 to $12.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 32.89% from the company’s current price.

Other research analysts also recently issued research reports about the company. Morgan Stanley boosted their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. HC Wainwright lifted their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, BTIG Research boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.14.

Personalis Stock Performance

Shares of Personalis stock opened at $9.03 on Friday. The business’s 50 day simple moving average is $8.82 and its 200 day simple moving average is $7.93. The firm has a market cap of $801.86 million, a PE ratio of -10.26 and a beta of 1.98. Personalis has a 52-week low of $2.83 and a 52-week high of $11.50.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The firm had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. As a group, equities research analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its stake in Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares during the period. Royal Bank of Canada lifted its holdings in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Howland Capital Management LLC grew its position in Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Personalis by 184.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after buying an additional 3,592 shares during the last quarter. Finally, Intech Investment Management LLC lifted its stake in shares of Personalis by 23.4% in the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after buying an additional 3,851 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis News Roundup

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Management set a 170% clinical test volume growth target for 2026, citing accelerating reimbursement and an MRD (minimal residual disease) strategy that should drive higher test volumes and revenue growth over the year. Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.26) vs. consensus ($0.31) and revenue of ~$17.34M vs. ~$17.12M consensus — the beat supports near‑term execution claims. Personalis: Q4 Earnings Snapshot / Press Release
• Neutral Sentiment: Earnings call transcripts and investor commentary are available (useful for details on margin levers, MRD commercialization timing and reimbursement cadence). Investors will be parsing management’s comments for credibility of the 2026 targets. Personalis (PSNL) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY‑2026 revenue guidance of $78.0M–$80.0M came in slightly below the ~$81M consensus, which tempers the optimism from the volume target and can weigh on near‑term multiple expansion. Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
• Negative Sentiment: Short interest rose ~21% in February to about 12.5% of shares outstanding (short‑ratio ~8.6 days), increasing downside pressure and volatility risk if results or guidance disappoint. Short Interest Report
• Negative Sentiment: The company remains unprofitable with a deeply negative net margin and ROE, meaning growth targets must translate to sustained revenue and margin improvement to justify a higher valuation. Personalis: Q4 Earnings Snapshot

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.